Hong XB, Yu ZL, Fu HB, Cai ZH, Chen J. Daptomycin and linezolid for severe methicillin-resistant Staphylococcus aureus psoas abscess and bacteremia: A case report and review of the literature. World J Clin Cases 2022; 10(8): 2550-2558 [PMID: 35434080 DOI: 10.12998/wjcc.v10.i8.2550]
Corresponding Author of This Article
Jie Chen, MD, Associate Chief Pharmacist, Department of Pharmacy, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Second Zhongshan Road, Yuexiu District, Guangzhou 510080, Guangdong Province, China. chenjiezs@163.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Mar 16, 2022; 10(8): 2550-2558 Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2550
Daptomycin and linezolid for severe methicillin-resistant Staphylococcus aureus psoas abscess and bacteremia: A case report and review of the literature
Xiao-Bing Hong, Ze-Lin Yu, Hong-Bo Fu, Ze-Hong Cai, Jie Chen
Xiao-Bing Hong, Ze-Lin Yu, Hong-Bo Fu, Department of Pharmacy, The Second Affiliated Hospital of Shantou University of Medical College, Shantou 515041, Guangdong Province, China
Ze-Hong Cai, Department of Pharmacology, Shantou University Medical College, Shantou 515041, Guangdong Province, China
Jie Chen, Department of Pharmacy, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China
Author contributions: Hong XB and Yu ZL were responsible for the article writing and data analysis; Hong XB and Yu ZL contributed equally to this study, and considered as co-first authors; Hong XB was the chief investigator and responsible for the data analysis; Chen J, Fu HB and Cai ZH were responsible for modifying the article; all authors contributed to the writing of the final manuscript.
Supported byShantou Medical and Health Science and Technology Program, No. SFK [2020] 66-23.
Informed consent statement: We obtained written informed consent from the patient, according to the rules of the Clinical Research Ethics Committee of the First Affiliated Hospital of Sun Yat-Sen University.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie Chen, MD, Associate Chief Pharmacist, Department of Pharmacy, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Second Zhongshan Road, Yuexiu District, Guangzhou 510080, Guangdong Province, China. chenjiezs@163.com
Received: August 31, 2021 Peer-review started: August 31, 2021 First decision: November 17, 2021 Revised: November 18, 2021 Accepted: January 27, 2022 Article in press: January 27, 2022 Published online: March 16, 2022 Processing time: 191 Days and 9.8 Hours
Abstract
BACKGROUND
Vancomycin remains a first-line treatment drug as per the treatment guidelines for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. However, a number of gram-positive cocci have developed resistance to several drugs, including glycopeptides. Therefore, there is an urgent need for effective and innovative antibacterial drugs to treat patients with infections caused by drug-resistant bacteria.
CASE SUMMARY
A 24-year-old male was admitted to hospital owing to lumbago, fever, and hematuria. Computed tomography (CT) results showed an abscess in the psoas major muscle of the patient. Repeated abscess drainage and blood culture suggested MRSA, and vancomycin was initiated. However, after day 10, CT scans showed abscesses in the lungs and legs of the patient. Therefore, treatment was switched to daptomycin. Linezolid was also added considering inflammation in the lungs. After 10 d of the dual-drug anti-MRSA treatment, culture of the abscess drainage turned negative for MRSA. On day 28, the patient was discharged without any complications.
CONCLUSION
This case indicates that daptomycin combined with linezolid is an effective remedy for bacteremia caused by MRSA with pulmonary complications.
Core Tip: We analyzed a case of severe methicillin-resistant Staphylococcus aureus (MRSA) bacteremia who failed to respond to first line treatment using vancomycin. We believe that our study makes a significant contribution to the literature because it indicates that daptomycin combined with linezolid is an effective remedy for bacteremia caused by MRSA with pulmonary complications.
